دورية أكاديمية
أعرض في EDS

The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.

التفاصيل البيبلوغرافية
العنوان: The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.
المؤلفون: Derksen JWG; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA, Utrecht, The Netherlands., Kurk SA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA, Utrecht, The Netherlands., Peeters PHM; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA, Utrecht, The Netherlands., Dorresteijn B; Danone Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands., Jourdan M; Danone Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands., van der Velden AMT; Department of Medical Oncology, Tergooi Hospital, Hilversum, The Netherlands., Nieboer P; Department of Medical Oncology, Wilhemina Hospital, Assen, The Netherlands., de Jong RS; Department of Medical Oncology, Martini Hospital, Groningen, The Netherlands., Honkoop AH; Department of Medical Oncology, Isala Hospital, Zwolle, The Netherlands., Punt CJA; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., May AM; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA, Utrecht, The Netherlands.
المصدر: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2020 Aug; Vol. 11 (4), pp. 919-928. Date of Electronic Publication: 2020 Feb 27.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Berlin : John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
Original Publication: Heidelburg : Springer-Verlag
مواضيع طبية MeSH: Colorectal Neoplasms/*physiopathology , Quality of Life/*psychology, Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis
مستخلص: Background: Skeletal muscle mass (SMM) loss is common in metastatic colorectal cancer (mCRC) patients and associated with poor clinical outcomes, including increased treatment-related toxicities and reduced survival. Muscle loss may contribute to reduced health-related quality of life (HRQoL), including fatigue. Our aim was to study associations between changes in SMM and concomitant changes in patient-reported HRQoL.
Methods: This was a secondary analysis of mCRC patients in the CAIRO3 randomized clinical trial who were-after initial treatment-randomized between maintenance treatment with capecitabine plus bevacizumab (CAP-B) and observation until first disease progression (PD1). Included patients had computed tomography images for SMM quantification, together with HRQoL assessments available at randomization and PD1. Changes in SMM (categorized as >2% loss, stable, and >2% gain) and HRQoL were computed between randomization and PD1. Changes in HRQoL score >10 points were considered clinically relevant. Associations between SMM and HRQoL changes were studied by multiple linear regression models. We also investigated whether associations differed by treatment arm for global health and the 13 other HRQoL subscales.
Results: Of 221 patients included (mean age 63.5 ± 8.4 years), 24% lost, 27% remained stable, and 49% gained SMM. At randomization, mean global health status was 73.5 ± 15.9 in the CAP-B arm and 75.1 ± 17.5 in the observation arm (P = 0.48). A stable or gain in SMM was significantly associated with a clinically relevant improvement in global health status (9.9 and 14.7 points, respectively), compared with patients who lost SMM. From the subscales that did not show significant differences between the two treatment arms, we found significant and clinically relevant associations for stable or gain in SMM with improved role functioning (12.0 and 17.9, respectively) and with less fatigue (-10.0 and -15.0, respectively) and pain (-16.3 for SMM gain). From the subscales that did show significantly different associations with SMM between the two treatment arms, we only found significant results in the observation arm. Here, associations were found for stable or gain in SMM with clinically relevant improved physical (12.4 for SMM gain), cognitive (10.7 and 9.7, respectively), and social functioning (15.5 and 15.6, respectively) as well as reduced appetite loss (-28.5 and -30.7, respectively).
Conclusions: In mCRC, SMM preservation during CAP-B and observation treatment is associated with significant and clinically relevant improvements in global health status and multiple functional and symptom scales. Studies are warranted to investigate whether interventions targeting SMM lead to improved HRQoL, fewer symptoms, and better functioning.
(© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.)
References: Qual Life Res. 2017 Jul;26(7):1745-1759. (PMID: 28315175)
Annu Rev Nutr. 2006;26:435-61. (PMID: 16602932)
Lancet Oncol. 2011 May;12(5):489-95. (PMID: 21296615)
Med Sci Sports Exerc. 2016 May;48(5):767-75. (PMID: 26694846)
Oncology. 2011;81(5-6):395-402. (PMID: 22269999)
J Appl Physiol (1985). 2004 Dec;97(6):2333-8. (PMID: 15310748)
Eur J Cancer Care (Engl). 2012 Jul;21(4):505-16. (PMID: 22309292)
Eur J Cancer Care (Engl). 2014 Jan;23(1):3-14. (PMID: 23834462)
Clin Nutr. 2013 Feb;32(1):65-72. (PMID: 22695408)
J Clin Oncol. 2014 Sep 10;32(26):2920-7. (PMID: 25113760)
Eur J Cancer Care (Engl). 2003 Dec;12(4):347-57. (PMID: 14982314)
Curr Opin Support Palliat Care. 2011 Dec;5(4):342-9. (PMID: 21986910)
J Clin Oncol. 2016 Apr 20;34(12):1339-44. (PMID: 26903572)
J Clin Oncol. 1998 Jan;16(1):139-44. (PMID: 9440735)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Cancer Epidemiol. 2014 Aug;38(4):448-54. (PMID: 24841870)
Clin Nutr. 2013 Oct;32(5):671-8. (PMID: 23845384)
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006. (PMID: 18923576)
Lancet. 2015 May 9;385(9980):1843-52. (PMID: 25862517)
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145. (PMID: 31661195)
Ann Oncol. 2018 May 1;29(5):1141-1153. (PMID: 29788170)
Stat Med. 1998 Mar 15-Apr 15;17(5-7):679-96. (PMID: 9549816)
Am J Clin Nutr. 2013 Oct;98(4):1012-9. (PMID: 23966429)
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):919-928. (PMID: 32107889)
Am J Clin Nutr. 2012 Dec;96(6):1346-53. (PMID: 23134880)
PLoS One. 2015 Jun 12;10(6):e0129742. (PMID: 26069972)
Clin Exp Metastasis. 2015 Jun;32(5):457-65. (PMID: 25899064)
J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):909-919. (PMID: 30144305)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
Arch Phys Med Rehabil. 2011 May;92(5):749-55. (PMID: 21530722)
Eur J Cancer. 2000 Sep;36(14):1796-807. (PMID: 10974628)
Cancer Nurs. 2014 Mar-Apr;37(2):E21-9. (PMID: 23357886)
J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):177-185. (PMID: 21475694)
Eur J Surg Oncol. 2015 Feb;41(2):186-96. (PMID: 25468746)
J Clin Oncol. 2005 Mar 1;23(7):1431-8. (PMID: 15684319)
J Clin Oncol. 2013 Apr 20;31(12):1539-47. (PMID: 23530101)
Acta Physiol (Oxf). 2014 Mar;210(3):489-97. (PMID: 24393306)
Nat Rev Dis Primers. 2018 Jan 18;4:17105. (PMID: 29345251)
Oncogenesis. 2016 Feb 22;5:e200. (PMID: 26900952)
Anticancer Drugs. 2008 Jun;19(5):447-64. (PMID: 18418212)
Acta Oncol. 2001;40(2-3):175-84. (PMID: 11441930)
Health Qual Life Outcomes. 2009 Dec 23;7:102. (PMID: 20030832)
Psychooncology. 2013 Jan;22(1):54-64. (PMID: 21905158)
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):623-629. (PMID: 28639432)
Lancet Oncol. 2008 Jul;9(7):629-35. (PMID: 18539529)
Nutr Cancer. 2014;66(4):583-9. (PMID: 24707897)
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):759-767. (PMID: 28493418)
فهرسة مساهمة: Keywords: Metastatic colorectal cancer; Quality of life; Skeletal muscle mass; Supportive care
تواريخ الأحداث: Date Created: 20200229 Date Completed: 20210825 Latest Revision: 20210825
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7432557
DOI: 10.1002/jcsm.12562
PMID: 32107889
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-6009
DOI:10.1002/jcsm.12562